Hepatology News

Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.

Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.

In our prior blog post, we discussed the frequent need to separate, from a legal and financial perspective, the real property from the practice in order to consummate a practice transaction with a private equity buyer.

Over three decades, changes to organ allocation policies were associated with reduced waitlist mortality and increased rates of liver transplant among children with pediatric acute liver failure, according to research in JAMA Surgery.

When investing, time in the market is arguably as important as well-publicized factors, such as rate of return, initial amount of investment (principal) and costs of investing.

The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.

Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.

Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.

Significant variations in global rates of infection, culture-positivity and drug resistance serve as a “call to action” to streamline antibiotic use and improve outcomes among inpatients with cirrhosis, according to researchers.